StreetInsider.com News Articles

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

MAPLE GROVE, Minn., May 20, 2026 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith), a subsidiary of Bora Pharmaceuticals Co., Ltd. (6472.TW and BORAY.OTCQX), today announced the recent launch of Cyclosporine Ophthalmic Emulsion 0.05%, therapeutically equivalent to the Reference Listed Drug (RLD), RESTASIS^®(cyclosporine ophthalmic emulsion) 0.05%. According to IQVIA, the cyclosporine ophthalmic emulsion market had U.S. sales of approximately $1.9 billion*. Bora received U.S. Food and Drug Administration (FDA) approval of its abbreviated

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

Wed, 20 May 2026 10:00:00 -0400

MacroGenics to sell manufacturing operations to Bora for $122.5 million

Mon, 11 May 2026 17:22:45 -0400

MacroGenics Inc. (NASDAQ: MGNX) announced it will sell its good manufacturing practice drug substance manufacturing operations to Bora Pharmaceuticals Co. Ltd. (OTCQX: BORAY) for $122.5 million upfront, according to a press release.

The transaction includes the transfer of MacroGenics' manufacturing site, contract development and manufacturing organization operations, and associated personnel to Bora. The deal encompasses both the Rockville, Maryland headquarters site, including an FDA-approved facility with 11,000 liters of total capacity, and a Frederick, Maryland warehouse.

Approximately 140 MacroGenics employees are expected to be hired by Bora as part of the transaction. MacroGenics will maintain a supply arrangement with Bora to support

MacroGenics to sell manufacturing operations to Bora for $122.5 million

Mon, 11 May 2026 17:22:45 -0400

Approximately 140 MacroGenics employees are expected to be hired by Bora as part of the transaction. MacroGenics will maintain a supply arrangement with Bora to support

MacroGenics to sell manufacturing operations to Bora for $122.5 million

Mon, 11 May 2026 17:22:45 -0400

Approximately 140 MacroGenics employees are expected to be hired by Bora as part of the transaction. MacroGenics will maintain a supply arrangement with Bora to support

MacroGenics to sell manufacturing operations to Bora for $122.5 million

Mon, 11 May 2026 17:22:45 -0400

Approximately 140 MacroGenics employees are expected to be hired by Bora as part of the transaction. MacroGenics will maintain a supply arrangement with Bora to support

MacroGenics to sell manufacturing operations to Bora for $122.5 million

Mon, 11 May 2026 17:22:45 -0400

Approximately 140 MacroGenics employees are expected to be hired by Bora as part of the transaction. MacroGenics will maintain a supply arrangement with Bora to support